Novo Nordisk on Friday reported strong early-stage results for its once-a-week obesity drug. Before the open, Novo Nordisk stock jumped while Eli Lilly fell. In the phase 1b/2a clinical trial, obese and overweight patients taking 20 milligrams of the amycretin drug saw an average weight reduction of 22% in 36 weeks. Patients taking a placebo experienced a 2% weight gain. Those taking 1.25mg over 20 weeks lost 9.7% of their body weight, with patients on 5mg over 28 weeks seeing a reduction of 16.2%.
